Pharma 2026: AI Accelerates Drug Time-to-Market

A Reuters analytical report dated January 26, 2026, records a shift in biotech. Major players (Novartis, GSK, Eli Lilly) are massively adopting AI. According to industry analysts, generative models allow reducing the time for preparing regulatory documents (for the FDA) by up to ~40%.

AI in clinical trials enables modeling patient reactions, reducing the need for live tests in early stages. This represents a potential saving of billions of dollars and months of waiting. The industry is moving from hype to operational efficiency.

Source: Reuters